Adamson Philip B. 4

What Happened
Philip B. Adamson, Chief Medical Officer of CVRx (CVRX), received two awards on Feb 27, 2026 totaling 103,000 restricted stock units (RSUs) (41,000 and 62,000) at $0.00 (derivative awards). He also disposed of 1,262 shares in an open-market sell on Mar 2, 2026 at a weighted average price of $7.90 (price range $7.90–$8.00), generating about $9,973. The sale was a sell-to-cover to satisfy tax withholding related to his equity award.

Key Details

• Transaction dates: RSU grants — Feb 27, 2026; sale — Mar 2, 2026. Filing date: Mar 16, 2026.
• Sale price and proceeds: 1,262 shares at a weighted average $7.90 (range $7.90–$8.00); proceeds ≈ $9,973.
• Holdings after transaction: Not specified in the filing.
• Notable footnotes:
  • RSU vesting: one award vests 25% each anniversary (F1); the other vests 25% on Feb 27, 2027 then 1/48th monthly thereafter (F5).
  • Includes 1,840 shares acquired under the issuer’s Employee Stock Purchase Plan (F2).
  • The sale was mandated to cover tax withholding via a sell-to-cover transaction (F3).
  • Weighted-average price covers multiple sale prices; full breakdown available on request (F4).
• Timeliness: Form 4 was filed on Mar 16, 2026; this is later than the typical 2-business-day SEC reporting window for Form 4s (the sale occurred Mar 2), so the filing appears delayed.

Context

• These were RSU grants (derivative awards recorded at $0.00) with multi-year vesting schedules; such grants are standard compensation and vest over time rather than indicating an immediate purchase.
• The small open-market sale was a sell-to-cover for taxes tied to the awards and is routine; it should not be interpreted alone as a directional insider bet on the stock.